throbber
IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF NEW JERSEY
`
`________________________________ x
`
`UNITED THERAPEUTICS CORPORATION,
`
`Plaintiff,
`
`Case N0.:
`
`vs.
`
`3:15-cv—05723-PGS—LHG
`
`WATSON LABORATORIES,
`
`INC.,
`
`Defendant.
`
`________________________________ x
`
`Job No. 504T4
`
`CONFIDENTIAL
`
`VIDEOTAPED DEPOSITION OF
`
`MAUREEN D. DONOVAN, Ph.D.
`
`Chicago, Illinois
`
`June 8, 2017
`
`9:05 a.m.
`
`REPORTED BY:
`
`SHERI E. LISS, CSR, RPR, CRR, CLR, RSA
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`
`PageI of9
`
`

`

`25
`
`2O
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PhD.
`
`The videotaped deposition of MAUREEN D.
`
`DONOVAN, Ph.D., called by the Plaintiff for
`
`examination,
`
`taken pursuant to the Code of Civil
`
`Procedure and the Rules of the Supreme Court of the
`
`State of Illinois pertaining to the taking of
`
`depositions for the purposes of evidence,
`
`taken
`
`before Sheri E. Liss, CSR NO. 084—002600,
`
`a
`
`Certified Shorthand Reporter within and for the
`
`State of Illinois, Registered Professional Reporter,
`
`Certified Realtime Reporter, at the offices of
`
`Winston & Strawn, 35 East Wacker Drive, Chicago,
`
`Illinois, on June 8, 2017 at the hour 9:05 o'clock
`
`3.111.
`
`
`
`[)AVII) FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 2 of 9
`
`

`

`25
`
`2O
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PILD.
`
`APPEARANCES :
`
`ON BEHALF OF THE PLAINTIFF:
`
`WILSON SONSINI GOODRICH & ROSATI
`
`1?00 K Street, NW
`
`Fifth Floor
`
`Washington, D.C. 20006—3814
`
`BY:
`
`VERONICA SUSANA ASCARRUNZ, ESQ.
`
`vascarrunz@wsgr.com
`
`—and—
`
`WILSON SONSINI GOODRICH & ROSATI
`
`12235 El Camino Road, Suite 200
`
`San Diego, CA 92130—3002
`
`BY:
`
`NATHAN SCHARN, ESQ.
`
`nscharn@wsgr.com
`
`
`
`DAVID FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`
`Page 3 of 9
`
`

`

`25
`
`20
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`C ONFIDENTIAI. - MAUREEN D. DONOVAN, PILD.
`
`APPEARANCES (continued) :
`
`ON BEHALF OF THE DEFENDANT:
`
`WINSTON & STRAWN
`
`35 West Wacker Drive, Suite 4100
`
`Chicago, Illinois
`
`60601
`
`BY: MICHAEL K. NUTTER, ESQ.
`
`mnutter@winston.com
`
`ALSO PRE SENT:
`
`JEREMY MANGAN, Videographer.
`
`
`
`DAVID FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 4 of 9
`
`

`

`
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PILD.
`
`INDEX
`
`MAUREEN DONOVAN, Ph.D.
`
`EXAMINAT ION
`
`Ms. Ascarrunz
`Mr. Nutter
`
`PAGE
`
`222
`
`E X H I B I T S
`
`NO.
`
`DESCRIPTION
`
`MARKED /REFERRED TO
`
`12
`
` L3
`
`21
`21
`21
`21
`54
`
`
`
`Donovan expert report dated
`April 14
`Expert Report of Paul
`Mydral
`U.S. Patent No. 6,521,212
`U.S. Patent No. 6,756,033
`U.S. Patent No. 9,358,240
`U.S. Patent No. 9,339,507
`Donovan expert report dated
`May 19, 2017
`Errata to Donovan expert
`report dated June 7, 2017
`Drug Compound
`U.S. Patent No. 5,234,953
`
`UTC_WAT_00459498
`UTC_WAT_00056638
`WATSON-TYVASO-Oll389l
`WATSON-TYVASO—Oll3980
`
`M q
`
`u'II-bw
`
`
`
`1
`
`ubUJMI—‘O
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`
`DAVID FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v- UNITED THERAPEUTICS, IPR2017—01622
`
`Page 5 of 9
`
`25
`
`20
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`

`

`25
`
`2O
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PhD.
`
`THE VIDEOGRAPHER: We are now on the
`
`record. This marks the beginning of Media No.
`
`l
`
`in
`
`the deposition of Dr. Maureen Donovan in the matter
`
`of United Therapeutics Corporation versus Watson
`
`Laboratories in the U.S. District Court, District of
`
`New Jersey. This deposition is being held at 35
`
`West Wacker Drive, Chicago, Illinois on June 8,
`
`2017. And the time is now 9:05 a.m.
`
`Will attorneys please identify
`
`themselves.
`
`MS. ASCARRUNZ: Veronica Ascarrunz on
`
`behalf of United Therapeutics Corporation. With me
`
`is my colleague Nathan Scharn. Both of us are at
`
`Wilson Sonsini Goodrich & Rosati.
`
`MR. NUTTER: Michael Nutter with the law
`
`firm Winston & Strawn LLP, here today on behalf of
`
`the defendant, Watson, as well as the witness.
`
`(Whereupon,
`
`the witness was
`
`sworn.)
`
`MAUREEN D. DONOVAN, Ph.D.,
`
`having been first duly sworn, was examined and
`
`testified as follows:
`
`EXAMINAT ION
`
`
`
`DAVID FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017—01622
`
`Page 6 of 9
`
`

`

`25
`
`2O
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PhD.
`
`144
`
`513?
`
`MR. NUTTER: Correct.
`
`MS. ASCARRUNZ: Okay.
`
`THE WITNESS:
`
`Do you have an iPhone?
`
`MR. NUTTER:
`
`I do. That's a timeline of
`
`various nebulizers at the bottom.
`
`MS. ASCARRUNZ:
`
`The URL looks different.
`
`Okay.
`
`I'll try to sort it out during a break.
`
`Maybe we could just move along.
`
`BY MS. ASCARRUNZ:
`
`Q.
`
`In Paragraph 329 of the Myrdal report,
`
`Dr. Myrdal wrote that the Opti—Neb —— "the first
`
`generation Opti—Neb device was
`
`'a simple device that
`
`merely provided a timer—controlled output of drug.'"
`
`Is that consistent with your
`
`understanding?
`
`A.
`
`Q.
`
`Yes, it is.
`
`Is it your understanding that that first
`
`generation Opti—Neb device was a constant output
`
`device?
`
`A.
`
`When the on switch was on, yes, it was a
`
`constant output device.
`
`Q.
`
`And do you agree with me that constant
`
`output is not a pulse?
`
`A.
`
`No.
`
`
`
`DAVID FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017—01622
`
`Page 7 of 9
`
`

`

`25
`
`2O
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PhD.
`
`150
`
`rapidly enough to manual control to deliver the
`
`pulse length that I've defined as a pulse.
`
`Q.
`
`Let's talk about the second generation
`
`of Opti-Neb.
`
`Do you understand that to be the
`
`Opti-Neb-ir?
`
`A.
`
`Q.
`
`Yes,
`
`I do.
`
`And in connection with the Opti—Neb—ir,
`
`in Paragraph 329, Dr. Myrdal indicates that the
`
`second generation product Opti—Neb—ir was also made
`
`commercially available.
`
`Is that your understanding as well?
`
`A.
`
`Q.
`
`It is.
`
`Where in the Myrdal report does
`
`Dr. Myrdal indicate or site a date for when the
`
`Opti—Neb—ir was commercially available?
`
`MR. NUTTER: Objection. Asked and
`
`answered.
`
`BY THE WITNESS:
`
`A.
`
`Well, as I pointed out
`
`in Paragraph 323,
`
`it must have been developed and available in 2004 or
`
`before based on the date of the EMEA discussion
`
`that's described in that paragraph. And otherwise,
`
`most of the dating and availability in the Opti—Neb
`
`family,
`
`information in this report is based in
`
`information provided by Dr. Biette.
`
`
`
`[)AVII) FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017—01622
`
`Page 8 of 9
`
`

`

`25
`
`2O
`
`21
`
`22
`
`23
`
`24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`CONFIDENTIAL - MAUREEN D. DONOVAN, PhD.
`
`153
`
`A.
`
`I'll rephrase.
`
`I don't recall from my
`
`review of the development reports seeing information
`
`about Opti—Neb devices being tested with
`
`treprostinil that were not commercially available
`
`devices or ready to be sold to UTC or whomever if
`
`that device were to go forward in a product
`
`development sense.
`
`Q.
`
`So your assumption is that any Opti—Neb
`
`devices on which United Therapeutics worked must
`
`have been commercially available?
`
`A.
`
`I don't think that's an assumption.
`
`I
`
`think it's just the documents I recall reviewing as
`
`I sit here today all speak to the Opti—Neb—ir and
`
`that was a commercially available nebulizer.
`
`Q.
`
`Is it Your understanding that the
`
`Opti-Neb-ir was a single device versus having
`
`multiple models that were termed Opti—Neb—ir?
`
`A.
`
`I don't have any specific knowledge of
`
`that.
`
`Q.
`
`A.
`
`What is the third generation Opti—Neb?
`
`Third generation Opti—Neb is the
`
`Opti—Neb—ir A—I—C—I.
`
`Q.
`
`And it's your opinion that that device
`
`was also made commercially available, correct?
`
`A.
`
`Yes, it is. Or let me think for just a
`
`
`
`DAVID FELDMAN WORLDWIDE, INC.
`450 Seventh Avenue — Ste 500, New York, NY 10123 1.800.642.1099
`
`UNITED THERAPEUTICS, EX. 2117
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017—01622
`
`Page 9 of 9
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket